Determination of epalrestat in human plasma by high performance liquid chromatography and its pharmacokinetics

Chinese Pharmaceutical Journal

Volumn 35, Issue 3, 2000, Pages 184-186

  Yu, Zicheng ^a   Lu, Shu ^a   Shao, Yundi ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Blood concentration; Epalrestat; HPLC; Pharmacokinetics

Indexed keywords

BLOOD EXTRACT; EPALRESTAT; METHANOL;

ACCURACY; ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; LINEAR SYSTEM; NORMAL HUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET;

EID: 0034009574     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Hotta N, Sakamoto N, Shigeta Y, et al. Clinical investigation of epalrestat, an aldose reductase inhibitor on diabetic neuropathy in a Japanese multicenter study, Int Congr Ser, 1995, 1084:79.
2. Goto Y, Hotta N, Shigeta Y, et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy, clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother, 1995, 49: 269.
3. Takie I. Effect of an aldose reductase inhibitor (kinedak) in Japanese NIDDM patients. Diabetes Res, 1996, 31:207